Combinatorial, additive and dose-dependent drug–microbiome associations

Archive ouverte

Forslund, Sofia | Chakaroun, Rima | Zimmermann-Kogadeeva, Maria | Markó, Lajos | Aron-Wisnewsky, Judith | Nielsen, Trine | Moitinho-Silva, Lucas | Schmidt, Thomas | Falony, Gwen | Vieira-Silva, Sara | Adriouch, Solia | Alves, Renato | Assmann, Karen | Bastard, Jean-Philippe | Birkner, Till | Caesar, Robert | Chilloux, Julien | Coelho, Luis Pedro | Fezeu, Leopold | Galleron, Nathalie | Helft, Gerard | Isnard, Richard | Ji, Boyang | Kuhn, Michael | Le Chatelier, Emmanuelle | Myridakis, Antonis | Olsson, Lisa | Pons, Nicolas | Prifti, Edi | Quinquis, Benoit | Roume, Hugo | Salem, Joe-Elie | Sokolovska, Nataliya | Tremaroli, Valentina | Valles-Colomer, Mireia | Lewinter, Christian | Søndertoft, Nadja | Pedersen, Helle Krogh | Hansen, Tue | Gøtze, Jens Peter | Køber, Lars | Vestergaard, Henrik | Hansen, Torben | Zucker, Jean-Daniel | Hercberg, Serge | Oppert, Jean-Michel | Letunic, Ivica | Nielsen, Jens | Bäckhed, Fredrik | Ehrlich, S. Dusko | Dumas, Marc-Emmanuel, M.-E. | Raes, Jeroen | Pedersen, Oluf | Clément, Karine | Stumvoll, Michael | Bork, Peer

Edité par CCSD ; Nature Publishing Group -

International audience. During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1-5. Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug-host-microbiome interactions in cardiometabolic disease.

Suggestions

Du même auteur

Microbiome and metabolome features of the cardiometabolic disease spectrum

Archive ouverte | Fromentin, Sebastien | CCSD

International audience. Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid cond...

Microbiome and metabolome features of the cardiometabolic disease spectrum

Archive ouverte | Fromentin, Sebastien | CCSD

International audience. Abstract Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-mo...

Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism

Archive ouverte | Belda, Eugeni | CCSD

International audience. Objectives: Gut microbiota is a key component in obesity and type 2 diabetes, yet mechanisms and metabolites central to this interaction remain unclear. We examined the human gut microbiome’s...

Chargement des enrichissements...